TY - JOUR
T1 - Functional gastrointestinal disorders negatively affect health-related quality of life in MS
AU - Marrie, Ruth Ann
AU - Leung, Stella
AU - Tyry, Tuula
AU - Cutter, Gary R.
AU - Fox, Robert
AU - Salter, Amber
N1 - Funding Information:
NARCOMS is a project of the Consortium of Multiple Sclerosis Centers (CMSC). NARCOMS is funded in part by the CMSC and the Foundation of the CMSC. The study was also supported in part by the Waugh Family Chair in Multiple Sclerosis and Research Manitoba Chair (to RAM). The funding source(s) had no role in the study design, collection, analysis or interpretation of the data, or in the decision to submit the article for publication.
Funding Information:
NARCOMS is supported in part by the Consortium of Multiple Sclerosis Centers (CMSC) and The Foundation of the CMSC. Ruth Ann Marrie is supported by the Waugh Family Chair in Multiple Sclerosis and a Manitoba Research Chair from Research Manitoba.
Funding Information:
T. Tyry and A. Salter report no disclosures. R. Fox receives consultant fees from Actelion, Biogen, Genentech, Novartis, and Teva. He has served on advisory committees of Biogen and Novartis. He also receives research support from Biogen (clinical trial contracts) and Novartis (research study support). G. Cutter serves on Data and Safety Monitoring Boards for AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Opko Biologics, Neurim, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva Pharmaceuticals, NHLBI (Protocol Review Committee), and NICHD (OPRU oversight committee). He also serves on consulting or advisory boards of Atara Biotherapeutics, Bioeq GmBH, Cerespir Inc, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Janssen Pharmaceuticals, Klein-Buendel Incorporated, MedImmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva Pharmaceuticals, Transparency Life Sciences, and TG Therapeutics. R. A. Marrie receives research funding from the CIHR, the National MS Society, the MS Society of Canada, the MS Scientific Research Foundation, Research Manitoba, the Consortium of MS Centers, Crohn’s and Colitis Canada, and the Waugh Family Chair in Multiple Sclerosis. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Publisher Copyright:
© 2020 American Academy of Neurology.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - ObjectiveTo determine the prevalence of functional gastrointestinal disorders, the demographic and clinical characteristics associated with the presence of functional gastrointestinal disorders, and the effects of these disorders with health-related quality of life (HRQOL) in a large, diverse population of persons with MS.MethodsIn 2014, we surveyed participants in the North American Research Committee on Multiple Sclerosis registry regarding functional gastrointestinal disorders using the Rome III questionnaire. Participants also reported their sociodemographic characteristics, disability status using Patient Determined Disease Steps, the presence of comorbid depression and anxiety, health behaviors, and HRQOL using the RAND-12. We determined the prevalence of each gastrointestinal disorder using the Rome III criteria. Using multivariable logistic regression models, we assessed the factors associated with the presence of each bowel disorder. Using linear regression, we evaluated the association between functional gastrointestinal disorders and HRQOL.ResultsOf 6,312 eligible respondents, 76.5% were female, with a mean (SD) age of 58.3 (10.2) years. Forty-two percent of respondents (n = 2,647) had a functional gastrointestinal disorder, most often irritable bowel syndrome (IBS), which affected 28.2% of participants. The prevalence of all functional gastrointestinal disorders increased with greater disability, and the prevalence of IBS increased with longer disease duration. After adjusting for sociodemographic and clinical characteristics, functional gastrointestinal disorders were associated with lower physical and mental HRQOL (both p < 0.0001).ConclusionsFunctional gastrointestinal disorders are common in MS and are associated with reduced HRQOL.
AB - ObjectiveTo determine the prevalence of functional gastrointestinal disorders, the demographic and clinical characteristics associated with the presence of functional gastrointestinal disorders, and the effects of these disorders with health-related quality of life (HRQOL) in a large, diverse population of persons with MS.MethodsIn 2014, we surveyed participants in the North American Research Committee on Multiple Sclerosis registry regarding functional gastrointestinal disorders using the Rome III questionnaire. Participants also reported their sociodemographic characteristics, disability status using Patient Determined Disease Steps, the presence of comorbid depression and anxiety, health behaviors, and HRQOL using the RAND-12. We determined the prevalence of each gastrointestinal disorder using the Rome III criteria. Using multivariable logistic regression models, we assessed the factors associated with the presence of each bowel disorder. Using linear regression, we evaluated the association between functional gastrointestinal disorders and HRQOL.ResultsOf 6,312 eligible respondents, 76.5% were female, with a mean (SD) age of 58.3 (10.2) years. Forty-two percent of respondents (n = 2,647) had a functional gastrointestinal disorder, most often irritable bowel syndrome (IBS), which affected 28.2% of participants. The prevalence of all functional gastrointestinal disorders increased with greater disability, and the prevalence of IBS increased with longer disease duration. After adjusting for sociodemographic and clinical characteristics, functional gastrointestinal disorders were associated with lower physical and mental HRQOL (both p < 0.0001).ConclusionsFunctional gastrointestinal disorders are common in MS and are associated with reduced HRQOL.
UR - http://www.scopus.com/inward/record.url?scp=85075999864&partnerID=8YFLogxK
U2 - 10.1212/CPJ.0000000000000668
DO - 10.1212/CPJ.0000000000000668
M3 - Article
C2 - 31750023
AN - SCOPUS:85075999864
SN - 2163-0402
VL - 9
SP - 381
EP - 390
JO - Neurology: Clinical Practice
JF - Neurology: Clinical Practice
IS - 5
ER -